Stem Cell Therapy Investment
What makes Q Therapeutics a smart investment opportunity? Here are a few factors to consider:
- Impressive new technology—Q-Cells® have been shown to provide robust myelination in disease models involving demyelination. The homologous animal cells have extended survival in animal models of ALS (Lou Gehrig's Disease).
- Strong, well-protected, world-wide intellectual property position—Q Therapeutics holds 16 issued patents with more currently pending. Patent protection extends until 2020, covering both the composition and use of Q-Cells® as well as other cells of the central nervous system.
- Clear, rapid path to market—Q-Cells® are produced using a patented process that should facilitate a faster, less-complicated path to market.
- Experienced management team and expert advisors—With decades of collective scientific, medical, business and legal experience, the Q Therapeutics team of executives and advisors are well qualified to turn the company's vision into a successful reality.
- Key partnerships—Q Therapeutics is working with leading universities (Johns Hopkins, University of Wisconsin, University of Utah, and Drexel University) and industry experts to demonstrate safety and efficacy for human use, to manufacture Q-Cells®, and to conduct clinical trials. We plan to conduct our first clinical trials at Johns Hopkins University.
- Short- and long-term potential—Q Therapeutics is in an outstanding position to bring new breakthrough products to market quickly, and then use those products as a foundation to develop next-generation cellular and non-cellular treatments.
|
COMPANY 
